PHGE-UN

Headquartered in Ness Ziona, Israel, BiomX Inc. is a clinical-stage biotechnology company established in 2015, dedicated to advancing microbiome-based therapies. The firm harnesses both naturally occurring and genetically engineered bacteriophage technologies to precisely identify and eliminate detrimental bacterial strains. BiomX's therapeutic efforts span conditions impacting skin appearance, as well as a spectrum of chronic diseases, including inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). The company's robust development pipeline includes several promising candidates. BX004, a phage-based treatment for cystic fibrosis patients suffering from persistent Pseudomonas aeruginosa respiratory infections, is presently undergoing Phase 1b/2a clinical evaluation. Another key asset, BX005, is a topical phage cocktail currently in Phase 1/2 clinical studies, engineered to combat Staphylococcus aureus (S. aureus), a bacterium linked to various disease manifestations. Additionally, BX003, an orally administered phage cocktail, is progressing through Phase 1b/2a trials, targeting a specific gut bacterium found in individuals with IBD and PSC. Beyond these, BiomX is engaged in a colorectal cancer initiative that utilizes engineered phages with diverse therapeutic payloads, delivered intravenously to neutralize Fusobacterium nucleatum bacteria residing within the tumor's microenvironment.